LINKS
ABOUT
SOCIAL
logo_allblue2.png

info@cardiaccs.com

Gaustadalléen 21

0349 Oslo
Norway

  • Twitter Social Icon
  • Black LinkedIn Icon

© 2020 by Cardiaccs

ADVANCED CARDIAC MONITORING 

THE UNMET NEED

THE SITUATION

More than 900,000 open heart surgeries are conducted each year in the US and EU. While this number has decreased in recent years, the complexity of the patients requiring surgery has increased.

THE CHALLENGE

Available techniques for monitoring the function of the heart after surgery tend to be either inaccurate, episodic or involve a high risk to the patient.

THE SOLUTION

Real-time heart function data allows for correct medication, early detection of complications and improved patient recovery, reducing cost for healthcare systems

“A disadvantage is that a catheter needs to be placed in the pulmonary vein. In the lung flow area with a balloon which bears the risk for arrhythmia, lung embolisms and infections. Therefore, in my opinion the disadvantages outweigh the benefit in most cases and therefore it has become so rare.” 

(German cardiothoracic surgeon)

OUR TECHNOLOGY

01 / SMART LEAD

Temporary pace leads are used routinely during cardiac surgery, all over the world. Cardiaccs' smart lead has an integrated sensor for monitoring cardiac function. 

02 / EASY TO USE

Cardiaccs' combined sensor and pace lead is placed and removed in the same way as standard temporary pace leads. 

03 / VITAL DATA

Cardiaccs' lead has an embedded accelerometer sensor that measures the velocity of each cardiac contraction. This is a vital parameter for monitoring the cardiac function 

“It is additional information that could reveal problems or complications faster than other parameters which have to be detected after a problem is suspected, e.g. a TEE is performed. I could imagine that a problem could be signaled at an earlier stage.” 

(German cardiothoracic surgeon)

“The benefits are that you might be able to nip a problem in the bud. Like ischemia and maybe rhythm issues.”  

(US cardiothoracic surgeon)

 

MEET CARDIACCS

OUR STORY

Cardiaccs was founded in 2009 by Prof. Erik Fosse as a result of 8 years of research and development by the Intervention Centre at Oslo University Hospital in cooperation with Buskerud and Vestfold University College. Since February 2016, the company has been ISO 13485 certified for design and development of medical devices. 

OUR VISION

Cardiovascular related diseases are the leading cause of hospitalization and death worldwide, and there is an increase of patients with complex cases where open heart surgeries are required. Cardiaccs wants to cover the urgent  unmet need for better cardiac monitoring to reduce morbidity and mortality in this patient group.

OUR TECHNOLOGY

Cardiaccs provides technology for measuring myocardial contractility, a vital parameter for monitoring of the cardiac function. With a continuous and accurate monitoring of the cardiac function, intra- and post-operative complications can be avoided, before a patient becomes critical.

 
 

TEAM

Lucile Souzy - Quality Manager

 

Lucile holds a masters degree in mechanical engineering and has several years of experience from medical device design, quality and regulatory compliance

MSc Jonas Tyssø - COO

 

Jonas holds a masters degree in engineering cybernetics from NTNU and has several years of engineering and R&D experience, both within tech startup and multinational IT. Jonas is heading the Cardisense project.

MSc Magnus Krogh - CTO

 

Magnus Krogh holds a masters degree in Biomedical Engineering and is PhD student at Oslo University where he has worked for several years on methods for monitoring the heart motion. Magnus develops software for the Cardisense technology

BOARD OF DIRECTORS

MD, PhD Erik Fosse - Founder and Chairman

 

Erik has a lifelong experience as a cardiothoracic surgeon and is head of department at the Intervention Centre at Oslo University Hospital. He has 10 patent applications and has participated in establishing multiple medical companies. 

Carl Christian Gilhuus-Moe, PhD, Member of the Board

Dr. Gilhuus-Moe has broad experience from various boards within the medical industry and as chairman of the Board of Oslo Medtech and Sonitor AS. He was the founding President and CEO of Dynal Biotech AS (part of Thermo Fisher Inc.). Dr. Gilhuus-Moe was a member of the executive group, Vice President and head of Hafslund-Nycomed ASA's diagnostic division (part of Abbott Labs).

Ulf Ower, Member of the Board

 

 

Ulf is an accountant and has 20 years of experience as economical advisor and business developer. He is CEO/CFO of 5 companies and owner of Finanstorget AS, an authorized accounting company.

QUALITY

ISO:13485 CERTIFIED

Cardiaccs has been ISO 13485 certified for design and development of medical devices since 2016. Quality has been at the center of everything we do, right from the beginning

BACKED BY